Meeting the needs of next-gen pharma with Aposave’s new commercial hub
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Meeting the needs of next-gen pharma with Aposave’s new commercial hub

12 Apr 2021

Sponsored by Aposave Sponsored by Visit Company
Meeting the needs of next-gen pharma with Aposave’s new commercial hub

As the pharma services arm of Abacus Medicine, UK-based Aposave has one of the strongest supply networks in the world, including more than 200 QA-approved EU and US suppliers. With its customised enterprise resource planning system, global distribution centres and experienced leadership team, Aposave aims to become a new-generation industry-leader in healthcare and pharma services.

Founded in 2004 by CEO Flemming Wagner and his father Dr John Wagner, Abacus Medicine started with the goal of improving accessibility to specialty medicines across Europe, and by 2019 had become the fastest growing distributor of original prescription medicines in the region.

While Aposave was created a few years earlier, it did not form into a healthcare and pharma business until 2018 when its first MD, Simon Estcourt, was recruited. Building on his extensive experience in the field, Estcourt and his teams have transformed accessibility to new medicines and addressed the global challenges of unmet medical needs over the past 15 years.

Now established as a key player in the healthcare and pharma services market, Aposave opened a new international commercial hub based in Farnborough, Hampshire, UK, which included welcoming a series of highly experienced executives to the team in 2019. In keeping with its global ambition, Aposave also has operations in the US, Hong Kong and Copenhagen.

According to Estcourt, “Aposave is an incredibly exciting company. Historically, no healthcare and pharma services organisation has had the backing of such a powerful parent organisation.

“With our portfolio of services from Clinical Trial Solutions to Managed Access Programs, Commercial Partnerships and our new Unlicensed Medicines Service, we are hugely excited about the new decade.”

“Combining the infrastructure and skills at Abacus Medicine with the experience and expertise here within Aposave, we truly have the capability of becoming the new generation of healthcare and pharma services organisation.”

Created to provide a range of services for pharmaceutical and biotech companies, as well as healthcare professionals around the world, Aposave continues its journey of innovation to meet the need of continuously supporting the next generation of pharmaceutical products.

Free Case Study

Drastically reducing the risk of unplanned comparator clinical trial costs

Comparator trials that weigh the benefits of bringing new drugs to market with the efficacy of existing therapies can be costly and unwieldy – particularly as the new therapy is usually sourced at phases II and III, leaving unused, expensive inventory for sponsors to deal with.

With patient recruitment problems also being a well-documented issue associated with clinical trials, this may also lead to unplanned build-up of expiry date issues with trial comparator inventory.

So, what’s the best solution? In this whitepaper, clinical trial services company Aposave explores the challenges and solutions faced by clients engaged in these trials. To learn more about how you can ethically and cost-effectively deal with these issues, download the free whitepaper below.

By clicking the “Submit” button above, you accept the Terms & Conditions and acknowledge that your data will be used as described in the Aposave Privacy Policy.

We will also collect and use the information you provide for carefully considered and specific purposes, where we believe we have a legitimate interest in doing so, for example to send you communications about similar products and services we offer. We will always give you an option to opt out of any future communications from us. You can find out more about our legitimate interest activity in our privacy policy here. ‘We’ includes Verdict Media Limited and other GlobalData brands as detailed here.